Skip to main content

Table 2 Prognostic factors for overall survival according to univariate and multivariate analyses in patients with both wild-type and mutant KRAS metastatic colorectal cancer after colorectal liver metastasectomy

From: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy

n = 220

Univariate

 

Multivariate

 

Variable

Hazard ratios (95% CI)

P-value

Hazard ratios (95% CI)

P-value

Age > 65 (y/o)

1.055 (0.729–1.526)

0.778

—

—

Initial stage IV at diagnosis

1.668 (1.129–2.462)

0.010

1.336 (0.885–2.016)

0.168

Bilobar liver metastases

1.494 (0.902–2.475)

0.119

—

—

Size > 5 cm

1.268 (0.803–2.002)

0.309

—

—

Number > 3

1.932 (1.287–2.903)

0.002

1.753 (1.151–2.670)

0.009

High grade

1.385 (0.915–2.096)

0.123

—

—

Margin R2

3.112 (1.350–7.172)

0.008

2.087 (1.200–6.567)

0.017

Extrahepatic metastasis

1.462 (0.937–2.282)

0.094

1.255 (0.798–1.973)

0.326

CIP2A overexpression

1.447 (1.001–2.092)

0.049

1.373 (0.946–1.992)

0.096

  1. Abbreviations: CIP2A Cancerous inhibitor of protein phosphatase 2A, KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog.